The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions

Alcoholism

Interventions

DRUG

125 mg AZD0530

Randomized to receive 125 mg of AZD0530

DRUG

50 mg AZD0530

Randomized to receive 50 mg of AZD0530

DRUG

Placebo

Trial Locations (1)

Hartford Hospital, Hartford

All Listed Sponsors

lead

Yale University

OTHER

NCT02262026 - The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism | Biotech Hunter | Biotech Hunter